Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro

Journal of Biomedical Materials Research - Part A

Volumn 67, Issue 2, 2003, Pages 458-466

  Andersson, Jonas ^a   Sanchez, Javier ^a   Ekdahl, Kristina Nilsson ^a,b   Elgue, Graciela ^a   Nilsson, Bo ^a   Larsson, Rolf ^a,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

^c Box 956 ^*  (Sweden)

Author keywords

Biocompatibility; Blood; Coagulation; Complement activation; Immobilized heparin

Indexed keywords

BLOOD; COAGULATION; TUBING;

PLATELET ACTIVATION;

BIOMEDICAL ENGINEERING;

ANTITHROMBIN; BIOMATERIAL; COMPLEMENT; COMPLEMENT FACTOR H; HEPARIN;

ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLOOD; BLOOD CLOTTING; COMPLEMENT ACTIVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EVALUATION; EXTRACORPOREAL CIRCULATION; GAS; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INCUBATION TIME; MATERIAL COATING; MODEL; NORMAL HUMAN; PROTEIN BINDING; ROTATION; SURFACE PROPERTY; TEMPERATURE; THROMBOCYTE ACTIVATION; TUBE; VELOCITY;

EID: 0347384110     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.10104     Document Type: Article

References (45)

1. Courtney JM, Lamba NM, Sundaram S, Forbes CD. Biomaterials for blood-contacting applications. Biomaterials 1994;15: 737-744.
2. Kazatchkine MD, Carreno MP. Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 1988;9:30-35.
3. Gemmell CH. Flow cytometric evaluation of material-induced platelet and complement activation. J Biomater Sci Polym Ed 2000;11:1197-1210.
4. Hong J, Nilsson Ekdahl K, Reynolds H, Larsson R, Nilsson B. A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. Biomaterials 1999;20:603-611.
5. Tang L, Liu L, Elwing HB. Complement activation and inflammation triggered by model biomaterial surfaces. J Biomed Mater Res 1998;41:333-340.
6. Van Teijlingen ME, Borgdorff P, Van Wijhe MH, Van Lambalgen TA, Wee PM, Tangelder GJ. In vivo visualization of hemodialysis-induced alterations in leukocyte-endothelial interactions. Kidney Int 2000;57:2608-2617.
7. Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987;13:89-95.
8. Kirklin JK. The postperfusion syndrome: Inflammation and the damaging effects of cardiopulmonary bypass. In: Tinker JH, editor. Cardiopulmonary bypass: Current concepts and controversies. Philadelphia: Saunders WB; 1989. p 3026-3041.
9. Greeley WJ, Ungerleider RM. Assessing the effect of cardiopulmonary bypass on the brain [editorial; comment]. Ann Thorac Surg 1991;52:417-419.
10. Hearn JA, King SB, Douglas JS, Carlin SF, Lembo NJ, Ghazzal ZM. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty. Initial results with a balloon-expandable, stainless steel design. Circulation 1993;88: 2086-2096.
11. Olsson C, Siegbahn A, Henze A, Nilsson B, Venge P, Joachimsson PO, Thelin S. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery. Scand Cardiovasc J 2000;34: 33-40.
12. Christensen K, Larsson R, Emanuelsson H, Elgue G, Larsson A. Heparin coating of the stent graft-effects on platelets, coagulation and complement activation. Biomaterials 2001;22:349-355.
13. Sanchez J, Lundquist PB, Elgue G, Larsson R, Olsson P. Measuring the degree of plasma contact activation induced by artificial materials. Thromb Res 2002;105:407-412.
14. Brynda E, Houska M, Jirouskova M, Dyr JE. Albumin and heparin multilayer coatings for blood-contacting medical devices. J Biomed Mater Res 2000;51:249-257.
15. Hsu L-C. Principles of heparin-coating techniques. Perfusion 1991;6:209-219.
16. Kocsis JF, Llanos G, Holmer E. Heparin-coated stents. J Long Term Eff Med Implants 2000;10:19-45.
17. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983;11:161-173.
18. van Der Giessen WJ, van Beusekom HM, Larsson R, Serruys P. Heparin-coated coronary stents. Curr Interv Cardiol Rep 1999; 1:234-240.
19. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222:525-559.
20. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Inhibition of the plasma contact activation system of immobilized heparin: Relation to surface density of functional antithrombin binding sites. J Biomed Mater Res 1997;37:37-42.
21. Pangburn MK, Atkinson MA, Meri S. Localization of the heparin-binding site on complement factor H. J Biol Chem 1991; 266:16847-16853.
22. Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol 1996;157: 5422-5427.
23. Blackmore TK, Hellwage J, Sadlon TS, Higgs N, Zipfel PF, Ward HM, Gordon DL. Identification of the second heparin-binding domain in human complement factor H. J Immunol 1998;160:3342-3348.
24. Prodinger WM, Hellwage J, Spruth M, Dierich MP, Zipfel PF. The C-terminus of factor H: Monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J 1998;331:41-47.
25. Gong J, Larsson R, Nilsson Ekdahl K, Mollnes TE, Nilsson UR, Nilsson B. Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol 1996;16:222-229.
26. Rodahl M, Höök F, Fredriksson C, Keller CA, Krozer A, Brzezinski P, Voinova M, Kasemo B. Simultaneous frequency and dissipation factor QCM measurements of biomolecular adsorption and cell adhesion. Faraday Discuss 1997;107:229-246.
27. Sauerbrey G. Verwendung von Schwingquarzen zur Wägung dünner Schichten und zur Mikrowägung. Zeitschrift für Physik 1959;155:206-222.
28. Caruso F, Furlong DN, Kingshott P. Characterization of ferritin adsorption onto gold. J Colloid Interface Sci 1997;186:129-140.
29. Höök F, Kasemo B, Nylander T, Fant C, Scott K, Elwing H. Variations in coupled water, viscoelastic properties and film thickness of a Mefp-1 film during adsorption and cross-linking: A quartz crystal microbalance with dissipation monitoring, ellipsometry and surface plasmon resonance study. Anal Chem 2001;73:5796-5804.
30. Höök F, Rodahl M, Brzezinski P, Kasemo B. Measurments using the quartz crystal microbalance technique of ferritin monolayers on methyl-thiolated gold: Dependence of energy dissipation and saturation coverage on salt concentration. J Colloid Interface Sci 1998;208:63-67.
31. Höök F, Rodahl M, Kasemo B, Brzezinski P. Structural changes in hemoglobin during adsorption to solid surfaces: Effects of pH, ionic strength, and ligand binding. Proc Natl Acad Sci USA 1998;95:12271-12276.
32. Rodahl M, Höök F, Krozer A, Brzezinski P, Kasemo B. Quartz-crystal microbalance setup for frequency and Q-factor measurments in gaseous and liquid. Rev Sci Instrum 1995;66(7):3924-3390.
33. Nilsson Ekdahl K, Nilsson B, Pekna M, Nilsson UR. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992;35:85-91.
34. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985;22:197-202.
35. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF. Large scale isolation of functionally active components of the human complement system. J Biol Chem 1981;256:3995-4006.
36. Kodama K, Pasche B, Olsson P, Swedenborg J, Adolfsson L, Larm O, Riesenfeld J. Antithrombin III binding to surface immobilized heparin and its relation to F Xa inhibition. Thromb Haemost 1987;58:1064-1067.
37. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976;8:413-416.
38. Elgue G, Sanchez J, Egberg N, Olsson P, Riesenfeld J. Effect of surface-immobilized heparin on the activation of adsorbed factor XII. Artif Organs 1993;17:721-726.
39. Egberg N, Overmark-Berggren I. Assay for Hageman factor (factor XII) in human plasma by means of chromogenic substrate for plasma kallikrein. Thromb Res 1983;31:875-880.
40. Larm O, Larsson R, Olsson P. Surface-imobilized heparin. In: Lane D, Lindahl U, editors. Heparin: Chemical and biological properties, clinical applications. London: Edward Arnold; 1989. p 597-608.
41. Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998;92:1661-1667.
42. Videm V, Mollnes TE, Bergh K, Fosse E, Mohr B, Hagve TA, Aasen AO, Svennevig JL. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. J Thorac Cardiovasc Surg 1999;117:803-809.
43. Weber N, Wendel HP, Ziemer G. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials 2002;23:429-439.
44. Skroeder NR, Kjellstrand P, Holmquist B, Nilsson U, Jacobson S. Increased amounts of C3a and the terminal complement complex at high dialysis blood-flow: The relation with dialysis efficiency. Nephron 1996;72:523-529.
45. Pasche B, Elgue G, Olsson P, Riesenfeld J, Rasmuson R. Binding of antithrombin to immobilized heparin under varying flow conditions. Artif Organs 1991;15:481-491.